Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension

作     者：Alberto Ferrarese Alberto Zanetto Giacomo Germani Patrizia Burra Marco Senzolo 

作者机构：Multivisceral Transplant Unit Department of Surgery Oncology and Gastroenterology Padua University Hospital 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2016年第8卷第24期

页      面：1012-1018页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Beta blockers Ascites Cirrhosis Portal hypertension 

摘      要：Non-selective beta blockers(NSBB) are commonly used to prevent portal hypertensive bleeding in ***, in the last years, the use of NSBB in critically decompensated patients, especially in those with refractory ascites, has been questioned, mainly for an increased risk of mortality and worsening of systemic hemodynamics. Moreover, even if NSBB have been reported to correlate with a higher risk of renal failure and severe infection in patients with advanced liver disease and hypotension, their use has been associated with a reduction of risk of spontaneous bacterial peritonitis, modification of gut permeability and reduction of bacterial translocation. This manuscript systematically reviews the published evidences about harms and benefits of the use of NSBB in patients with decompensated cirrhosis.